Malcolm D. Mason

Active 1989–2024

Also published as
Malcolm D Mason
119
Papers
43,162
Citations
93
h-index
119
i10-index

Citations

Citations per year for Malcolm D. Mason1985: 1 citations1992: 2 citations1993: 6 citations1994: 1 citations1995: 1 citations1996: 4 citations1997: 5 citations1998: 2 citations1999: 3 citations2000: 4 citations2001: 4 citations2002: 20 citations2003: 25 citations2004: 42 citations2005: 53 citations2006: 67 citations2007: 91 citations2008: 112 citations2009: 116 citations2010: 157 citations2011: 168 citations2012: 251 citations2013: 281 citations2014: 308 citations2015: 365 citations2016: 375 citations2017: 483 citations2018: 553 citations2019: 1,668 citations2020: 1,693 citations2021: 1,640 citations2022: 1,285 citations2023: 868 citations2024: 1,459 citations2025: 574 citations2026: 21 citations1986–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,216 citing papers, 19% of this breakdownChina: 1,450 citing papers, 8.5% of this breakdownUnited Kingdom: 1,349 citing papers, 8% of this breakdownItaly: 1,141 citing papers, 6.7% of this breakdownGermany: 1,112 citing papers, 6.6% of this breakdownNetherlands: 765 citing papers, 4.5% of this breakdownCanada: 739 citing papers, 4.4% of this breakdownFrance: 678 citing papers, 4% of this breakdownAustralia: 574 citing papers, 3.4% of this breakdownSwitzerland: 473 citing papers, 2.8% of this breakdownSpain: 452 citing papers, 2.7% of this breakdownBelgium: 439 citing papers, 2.6% of this breakdown
0%19%Other 26.8%

Fields

  • Medicine61.7%
  • Biochemistry, Genetics and Molecular Biology30.4%
  • Immunology and Microbiology3%
  • Engineering0.8%
  • Health Professions0.6%
  • Computer Science0.6%
  • Other2.9%

Topics

  • Prostate Cancer Treatment and Research13.4%
  • Prostate Cancer Diagnosis and Treatment12.9%
  • Extracellular vesicles in disease7.5%
  • MicroRNA in disease regulation4.3%
  • Radiopharmaceutical Chemistry and Applications2.5%
  • Advanced Radiotherapy Techniques2.1%
  • Other57.3%

Coauthors

All papers

Open in search
  1. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 2,814

  2. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 751

  3. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes - New England Journal of Medicine 2017 cited by 1,772

  4. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 1,126

  5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar - The Lancet 2015 cited by 1,968

  6. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 2,650

  7. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes - The Lancet 2018 cited by 1,262

  8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Urology 2016 cited by 3,260

  9. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 517

  10. Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation

    Authors: , , , , - Cancer Research 2010 cited by 834

  11. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey and 73 more - The Lancet 2021 cited by 367

  12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , - European Urology 2016 cited by 1,442

  13. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip A. Powell, Stephen M. Prescott, Derek J. Rosario, Edward Rowe, Michael J. Davis, Emma L. Turner, Richard M. Martin, David E. Neal - New England Journal of Medicine 2016 cited by 1,328

  14. Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression

    Authors: , , , , , - The Journal of Immunology 2008 cited by 561

  15. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Urology 2017 cited by 533

  16. Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production

    Authors: , , , , - The Journal of Immunology 2011 cited by 537

  17. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanna Gale, Stephanie Gibbs, Anna Lydon, Ashok Nikapota, Aurelius Omlin, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Sarah Rudman, Narayanan Srihari, Matthew Simms, Jacob Tanguay, Shaun Tolan, John Wagstaff, Jan Wallace, J. Wylie, Anjali Zarkar, Matthew R. Sydes, Mahesh Parmar, Nicholas D. James - Annals of Oncology 2019 cited by 398

  18. Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59

    Authors: , , , , - European Journal of Immunology 2003 cited by 337

  19. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan C. Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise Brown, Mahesh Parmar, Nicholas D. James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, D. Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, M. Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan B. McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry M. Taylor, John D. Graham and 80 more - The Lancet Oncology 2023 cited by 102

  20. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry

    Authors: , , , , , , , - Journal of Immunological Methods 2001 cited by 553

  21. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes

    Authors: , , , , , , , , , , , - Oncogene 2014 cited by 424

  22. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology Focus 2019 cited by 242

  23. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, M. Kagzi, Anna Lydon, Joe M. O’Sullivan, Sangeeta Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Srihari, Jacob Tanguay, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trial Collaborative Group - PLoS Medicine 2022 cited by 121

  24. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Prantik Das, Dan Ford, Joanna Gale, Warren Grant, Emma Gray, Peter Hoskin, Mohammad Muneeb Khan, Caroline Manetta, Neil McPhail, Joe M. O’Sullivan, Omi Parikh, Carla Perna, Carmel Pezaro, Andrew Protheroe, Angus Robinson, Sarah Maria Rudman, D.J. Sheehan, Narayanan Srihari, Isabel Syndikus, Jacob Tanguay, Carys Thomas, Salil Vengalil, John Wagstaff, James Wylie, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trials Collaborative Group - International Journal of Cancer 2022 cited by 77